Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy-Reference-Cited by-同舟云学术

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

Published:2011-11-25 Issue:5 Volume:19 Page:768-778
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Bartucci M,Svensson S,Romania P,Dattilo R,Patrizii M,Signore M,Navarra S,Lotti F,Biffoni M,Pilozzi E,Duranti E,Martinelli S,Rinaldo C,Zeuner A,Maugeri-Saccà M,Eramo A,De Maria R

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cdd2011170.pdf

Reference39 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.

2. Travis WD, Travis LB, Devesa SS . Lung cancer. Cancer 1995; 75 (1 Suppl): 191–202.

3. Collins LG, Haines C, Perkel R, Enck RE . Lung cancer: diagnosis and management. Am Fam Physician 2007; 75: 56–63.

4. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281–16286.

5. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504–514.

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Based on machine learning, CDC20 has been identified as a biomarker for postoperative recurrence and progression in stage I & II lung adenocarcinoma patients;Frontiers in Oncology;2024-07-24

2. miRNAs in radiotherapy resistance of cancer; a comprehensive review;Cell Biochemistry and Biophysics;2024-05-28

3. Nobiletin Inhibits Breast Cancer Stem Cell by Regulating the Cell Cycle: A Comprehensive Bioinformatics Analysis and In Vitro Experiments;Nutrition and Cancer;2024-05-09

4. Hallmarks of cancer stemness;Cell Stem Cell;2024-05

5. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets;Cancers;2024-03-13